Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
BLGO US​

Biolargo, Inc.(BLGO US)

$0.07+0.000.00%Ext:$0.07+0.001.53%(Market Closed · 20:00:00 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Biolargo, Inc. — Company Profile

BioLargo, Inc. pioneers the invention, development, and commercialization of sophisticated platform technologies. The company is dedicated to tackling critical environmental challenges, such as per- and polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater purification, managing industrial odors and volatile organic compounds (VOCs), enhancing air quality, and controlling infections. Backed by numerous issued patents, BioLargo maintains a robust product pipeline and extends its expertise through comprehensive environmental engineering services. Among its notable innovations are the Advanced Oxidation system, a water treatment solution generating potent oxidative and energetic iodine species; the Aqueous Electrostatic Concentrator, specifically designed for eliminating PFAS from water; CupriDyne Clean industrial products, which effectively neutralize stubborn odors and VOCs across various industrial settings; and specialized advanced wound care products. Established in 1991, BioLargo, Inc. is headquartered in Westminster, California.

Sector
Basic Materials
Industry
Chemicals
Exchange
UU
CEO
Dennis Calvert
Headquarters
Westminster, CA, US
IPO Date
Mar 22, 2007
Employees
45
Website
www.biolargo.com

Key Metrics

Price
$0.08
Market Cap
$25.95M
Revenue (TTM)
$1.11M
Net Income (TTM)
$-2286000.00
EPS (TTM)
-0.01
P/E (TTM)
-2.01
P/B (TTM)
14.53
Dividend Yield
0.00%
ROE (TTM)
-128.00%
ROA (TTM)
-26.69%
Operating Margin
-2.87%
Beta
0.52

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

BioLargo, Inc. pioneers the invention, development, and commercialization of sophisticated platform technologies. The company is dedicated to tackling critical environmental challenges, such as per- and polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater purification, managing industrial odors and volatile organic compounds (VOCs), enhancing air quality, and controlling infections. Backed by numerous issued patents, BioLargo maintains a robust product pipeline and extends its expertise through comprehensive environmental engineering services. Among its notable innovations are the Advanced Oxidation system, a water treatment solution generating potent oxidative and energetic iodine species; the Aqueous Electrostatic Concentrator, specifically designed for eliminating PFAS from water; CupriDyne Clean industrial products, which effectively neutralize stubborn odors and VOCs across various industrial settings; and specialized advanced wound care products. Established in 1991, BioLargo, Inc. is headquartered in Westminster, California.

Website
www.biolargo.com
Location
Westminster, CA, US
Phone888 400 2863
Employees45
CEODennis Calvert
SectorBasic Materials
Industry
Chemicals
IPO DateMar 22, 2007

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(1.1K)

Expand
  • DEF 14ADefinitive proxy statement19 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 8-K/ARegulation FD Disclosure11 Sep
  • 8-KRegulation FD Disclosure11 Sep
  • 10-QQ2ended 30 Jun 202614 Aug
  • 4Statement of changes in beneficial ownership7 Jul
  • 4Statement of changes in beneficial ownership2 Jul
  • 4Statement of changes in beneficial ownership2 Jul
  • 4Statement of changes in beneficial ownership2 Jul
  • 4Statement of changes in beneficial ownership2 Jul
  • 4Statement of changes in beneficial ownership2 Jul
  • 4Statement of changes in beneficial ownership24 Jun
  • 10-QQ1ended 31 Mar 202615 May
  • 8-KRegulation FD Disclosure6 May
  • 8-KRegulation FD Disclosure4 May

News

  • BioLargo Subsidiary Clyra Medical to Exhibit at SAWC Fall 2026 in Las Vegas13 Oct
  • BioLargo, Inc. (BLGO) Q2 2026 Earnings Call Transcript11 Sep
  • BioLargo Canada and Tu Nipi Form Indigenous-Led Partnership to Treat Oil Sands Process Water and More10 Sep
  • BioLargo Townhall and Q2 2026 Earnings Results Webcast and Conference Call on Thursday, September 10th, 2026 - 4:00 PM Eastern Time9 Sep
  • BioLargo's Subsidiary Clyra Medical Adds Third Distribution Channel Accelerating Commercial Rollout of ViaClyr Wound Irrigation Solution3 Sep
  • BioLargo, Inc. to Present at the Inaugural Nasdaq / LD Micro Summit on September 9, 20261 Sep
  • Critical Review: BioLargo (NASDAQ:BLGO) and Akzo Nobel (OTCMKTS:AKZOD)28 Aug
  • BioLargo to Participate in Gabelli Funds' 4th Annual PFAS Symposium in New York25 Aug
  • Gabelli To Host 4th Annual PFAS Symposium24 Aug
  • BioLargo Reports Second Quarter 2026 Results; Revenue Up 12% Sequentially, Gross Margin Expands to 54%17 Aug
  • BioLargo's Lake Stockholm AEC Installation passes six months of PFAS remediation Topping Two Million Gallons3 Aug
  • BioLargo Joins New Jersey Institute of Technology-Led PFAS Consortium; President Tonya Chandler Appointed to Board of Directors30 Jul
  • BioLargo Equipment Solutions & Technologies' "PFAS Lady" to Teach PFAS 101 at 41st Annual Tri-State Seminar29 Jul
  • BioLargo PFAS Treatment Technology Featured in The Disruptive Quarterly27 Jul

Mentions in Filings

  • ?
    April 10, 2026 Dennis Calvert Chief Executive Officer <strong>BioLargo, Inc.</strong> 14921 Chestnut St. Westminster, CA 92683 Re: BioLargo, Inc. Registration Statement on Form S-1 Filed April 09, 2026 File No. 333-294948 Dear Dennis Calvert: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its managem …
    Biolargo, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·10 Apr·10 Apr
  • ?
    April 10, 2026 Dennis Calvert Chief Executive Officer <strong>BioLargo, Inc.</strong> 14921 Chestnut St. Westminster, CA 92683 Re: BioLargo, Inc. Registration Statement on Form S-1 Filed April 09, 2026 File No. 333-294948 Dear Dennis Calvert: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management ar …
    Biolargo, Inc.·LETTER - UPLOAD - Filing review upload·10 Apr·10 Apr
  • ?
    April 10, 2026 Dennis Calvert Chief Executive Officer <strong>BioLargo, Inc.</strong> 14921 Chestnut St. Westminster, CA 92683 Re: BioLargo, Inc. Registration Statement on Form S-1 Filed April 09, 2026 File No. 333-294947 Dear Dennis Calvert: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management ar …
    Biolargo, Inc.·LETTER - UPLOAD - Filing review upload·10 Apr·10 Apr
  • ?
    April 10, 2026 Dennis Calvert Chief Executive Officer <strong>BioLargo, Inc.</strong> 14921 Chestnut St. Westminster, CA 92683 Re: BioLargo, Inc. Registration Statement on Form S-1 Filed April 09, 2026 File No. 333-294947 Dear Dennis Calvert: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its managem …
    Biolargo, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·10 Apr·10 Apr

Key Stats

Trading

Px/Chg 1D$0.08 / +3.03%
Prev Close$0.09
% of 52Wk H37.98%
Avg Volume362.22K
Beta0.52
Mkt Cap25.95M
FD Mkt Cap28.08M

Float

Shrs Out/Float320.88M / 276.13M
Short Float0.00%
Days to Cover1.00
Stock Repurchased$0.00

Current Valuation

EV25.52M
EV/EBITDA-1.61
EV/Sales4.55
P/B14.53
P/S4.63
FCF Yield-11.36%
ROE-128.00%
ROA-26.69%
Current Ratio1.10

Estimates

P/E-2.01
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-19.27-11.82-29.06-30.28-13.83-11.36
Price / Sales22.219.038.334.0966.3123.28
Price / Book Value11.7310.8914.888.2210.1114.53
Price / Free Cash Flow-20.80-17.52-35.82-16.38-25.48-8.80
ENTERPRISE VALUE METRICS
Enterprise Value55.949.997.369.038.025.5
Enterprise Value / Sales20.978.487.963.8861.6322.89
Enterprise Value / EBITDA-13.27-9.78-23.26-16.99-8.06-8.25
Enterprise Value / EBIT-12.60-9.82-21.42-15.98-7.83-7.97

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue32.3%2.55.912.217.87.8
Gross Income32.6%1.12.96.27.93.4
EBITDA21.4%-6.7-5.1-4.2-4.1-14.5
EBIT22.2%-6.7-5.1-4.5-4.3-14.8
Net Income12.4%-7.4-4.5-3.5-2.4-11.8
EPS (Diluted)6.5%-0.03-0.02-0.01-0.01-0.04
BALANCE SHEET
Cash & ST Inv41.7%1.01.93.53.53.9
Total Assets28.8%3.04.98.210.58.3
Total Liabilities34.2%2.12.84.04.56.8
Total Shareholder Equity-3.5%4.74.96.88.94.0
CASH FLOW
Net Operating Cash Flow20.5%-3.9-2.8-2.4-3.2-8.3
Cap Ex7.8%-0.0-0.3-0.5-1.2-0.0
Free Cash Flow20.4%-4.0-3.0-2.8-4.4-8.3

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)0.07
Basic Shares320.88
Market Cap22.5
Diluted Shares318.70
Fully Diluted Shares Outstanding318.70
Fully Diluted Market Cap22.3
+Consolidated Debt5.7
−In-the-Money Convertible Debt—
+Capital Leases1.4
+Operating Leases—
−Cash & Equivalents-4.1
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-2.0
+Pension Liabilities—
Enterprise Value22.0

Segment data

Revenue

by Products and services

  • Product74%
  • Service26%

Related companies

Akzo Nobel Nv

AKZOY US

Solstice Advanced Materials Inc.

SOLS US

Balchem Corp

BCPC US

Ingevity Corp

NGVT US

Innospec Inc.

IOSP US

Chemours Co

CC US

OLIN Corp

OLN US

Huntsman CORP

HUN US

Fmc Corp

FMC US

Standard Lithium Ltd.

SLI US

Aduro Clean Technologies Inc.

ADUR US

Loop Industries, Inc.

LOOP US